# Prime Medicine, Inc.: financial statements, quarterly

PRME · Nasdaq · CIK 1894562 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/prme.md) · [Financials](/companies/prme/financials.md) · [Filings](/companies/prme/filings.md) · [Insiders](/companies/prme/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/prme/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001628280-24-047130.md) | [0.0 d](/filings/0001628280-25-008884.md) | [0.6](/filings/0001628280-25-023486.md) | [0.0](/filings/0001628280-25-038619.md) | [0.2](/filings/0001628280-25-050422.md) | [2.2 d](/filings/0001628280-26-013569.md) | [1.5](/filings/0001628280-25-023486.md) | [1.1](/filings/0001628280-25-038619.md) | [1.2](/filings/0001628280-25-050422.md) | [0.8 d](/filings/0001628280-26-013569.md) | not reported | not reported |
| Research and development | $m | [41.0](/filings/0001628280-24-047130.md) | [41.5 d](/filings/0001628280-25-008884.md) | [37.8](/filings/0001628280-25-023486.md) | [43.1](/filings/0001628280-25-038619.md) | [40.3](/filings/0001628280-25-050422.md) | [34.1 d](/filings/0001628280-26-013569.md) | [40.6](/filings/0001628280-26-031726.md) | [41.4](/filings/0001628280-26-053883.md) | [44.0](/filings/0001628280-25-050422.md) | [34.7 d](/filings/0001628280-26-013569.md) | [34.1](/filings/0001628280-26-031726.md) | [33.4](/filings/0001628280-26-053883.md) |
| Operating income | $m | [(51.5)](/filings/0001628280-24-047130.md) | [(68.0) d](/filings/0001628280-25-008884.md) | [(48.3)](/filings/0001628280-25-023486.md) | [(55.7)](/filings/0001628280-25-038619.md) | [(54.2)](/filings/0001628280-25-050422.md) | [(44.2) d](/filings/0001628280-26-013569.md) | [(52.4)](/filings/0001628280-26-031726.md) | [(53.4)](/filings/0001628280-26-053883.md) | [(54.0)](/filings/0001628280-25-050422.md) | [(48.6) d](/filings/0001628280-26-013569.md) | [(50.7)](/filings/0001628280-26-031726.md) | [(43.3)](/filings/0001628280-26-053883.md) |
| Income tax | $m | [(0.1)](/filings/0001628280-24-047130.md) | [0.0 d](/filings/0001628280-25-008884.md) | [0.1](/filings/0001628280-25-023486.md) | [(0.1)](/filings/0001628280-25-038619.md) | [0.0](/filings/0001628280-24-047130.md) | [0.0 d](/filings/0001628280-26-013569.md) | [0.0](/filings/0001628280-25-023486.md) | [0.0](/filings/0001628280-25-038619.md) | not reported | not reported | not reported | not reported |
| Net income | $m | [(50.7)](/filings/0001628280-24-047130.md) | [(65.6) d](/filings/0001628280-25-008884.md) | [(45.8)](/filings/0001628280-25-050422.md) | [(55.3)](/filings/0001628280-25-050422.md) | [(52.5)](/filings/0001628280-25-050422.md) | [(42.3) d](/filings/0001628280-26-013569.md) | [(51.9)](/filings/0001628280-26-053883.md) | [(52.6)](/filings/0001628280-26-053883.md) | [(50.6)](/filings/0001628280-25-050422.md) | [(46.1) d](/filings/0001628280-26-013569.md) | [(49.1)](/filings/0001628280-26-053883.md) | [(42.1)](/filings/0001628280-26-053883.md) |
| Diluted EPS | $ per share | [(0.55)](/filings/0001628280-24-047130.md) | not reported | [(0.44)](/filings/0001628280-25-023486.md) | [(0.46)](/filings/0001628280-25-038619.md) | [(0.44)](/filings/0001628280-25-050422.md) | not reported | [(0.40)](/filings/0001628280-26-031726.md) | [(0.41)](/filings/0001628280-26-053883.md) | [(0.32)](/filings/0001628280-25-050422.md) | not reported | [(0.28)](/filings/0001628280-26-031726.md) | [(0.24)](/filings/0001628280-26-053883.md) |
| Basic EPS | $ per share | [(0.55)](/filings/0001628280-24-047130.md) | not reported | [(0.44)](/filings/0001628280-25-023486.md) | [(0.46)](/filings/0001628280-25-038619.md) | [(0.44)](/filings/0001628280-25-050422.md) | not reported | [(0.40)](/filings/0001628280-26-031726.md) | [(0.41)](/filings/0001628280-26-053883.md) | [(0.32)](/filings/0001628280-25-050422.md) | not reported | [(0.28)](/filings/0001628280-26-031726.md) | [(0.24)](/filings/0001628280-26-053883.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [44.0](/filings/0001628280-24-047130.md) | [41.6](/filings/0001628280-25-008884.md) | [94.2](/filings/0001628280-25-023486.md) | [55.6](/filings/0001628280-25-038619.md) | [118](/filings/0001628280-25-050422.md) | [182](/filings/0001628280-26-013569.md) | [91.9](/filings/0001628280-26-031726.md) | [53.8](/filings/0001628280-26-053883.md) | [71.4](/filings/0001628280-25-050422.md) | [63.0](/filings/0001628280-26-053883.md) | [64.1](/filings/0001628280-26-031726.md) | [47.5](/filings/0001628280-26-053883.md) |
| Current assets | $m | [185](/filings/0001628280-23-036777.md) | [143](/filings/0001628280-25-008884.md) | [218](/filings/0001628280-24-022473.md) | [171](/filings/0001628280-24-035893.md) | [246](/filings/0001628280-24-047130.md) | [212](/filings/0001628280-26-013569.md) | [164](/filings/0001628280-25-023486.md) | [121](/filings/0001628280-25-038619.md) | [231](/filings/0001628280-25-050422.md) | [181](/filings/0001628280-26-053883.md) | [138](/filings/0001628280-26-031726.md) | [96.8](/filings/0001628280-26-053883.md) |
| Total assets | $m | [239](/filings/0001628280-23-036777.md) | [194](/filings/0001628280-25-008884.md) | [311](/filings/0001628280-24-022473.md) | [260](/filings/0001628280-24-035893.md) | [333](/filings/0001628280-24-047130.md) | [298](/filings/0001628280-26-013569.md) | [328](/filings/0001628280-25-023486.md) | [279](/filings/0001628280-25-038619.md) | [385](/filings/0001628280-25-050422.md) | [343](/filings/0001628280-26-053883.md) | [295](/filings/0001628280-26-031726.md) | [249](/filings/0001628280-26-053883.md) |
| Current liabilities | $m | [39.4](/filings/0001628280-23-036777.md) | [56.4](/filings/0001628280-25-008884.md) | [24.4](/filings/0001628280-24-022473.md) | [20.7](/filings/0001628280-24-035893.md) | [37.9](/filings/0001628280-24-047130.md) | [38.0](/filings/0001628280-26-013569.md) | [34.3](/filings/0001628280-25-023486.md) | [34.1](/filings/0001628280-25-038619.md) | [35.0](/filings/0001628280-25-050422.md) | [37.4](/filings/0001628280-26-053883.md) | [36.3](/filings/0001628280-26-031726.md) | [31.7](/filings/0001628280-26-053883.md) |
| Total liabilities | $m | [45.2](/filings/0001628280-23-036777.md) | [60.8](/filings/0001628280-25-008884.md) | [67.6](/filings/0001628280-24-022473.md) | [63.1](/filings/0001628280-24-035893.md) | [143](/filings/0001628280-24-047130.md) | [144](/filings/0001628280-26-013569.md) | [221](/filings/0001628280-25-023486.md) | [218](/filings/0001628280-25-038619.md) | [223](/filings/0001628280-25-050422.md) | [222](/filings/0001628280-26-053883.md) | [218](/filings/0001628280-26-031726.md) | [209](/filings/0001628280-26-053883.md) |
| Shareholders' equity | $m | [194](/filings/0001628280-24-047130.md) | [133](/filings/0001628280-26-013569.md) | [244](/filings/0001628280-25-050422.md) | [197](/filings/0001628280-25-050422.md) | [190](/filings/0001628280-25-050422.md) | [153](/filings/0001628280-26-053883.md) | [107](/filings/0001628280-26-053883.md) | [60.9](/filings/0001628280-26-053883.md) | [162](/filings/0001628280-25-050422.md) | [121](/filings/0001628280-26-053883.md) | [76.7](/filings/0001628280-26-053883.md) | [39.8](/filings/0001628280-26-053883.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(39.2) d](/filings/0001628280-24-047130.md) | [(43.9) d](/filings/0001628280-25-008884.md) | [(67.7)](/filings/0001628280-25-023486.md) | [(45.5) d](/filings/0001628280-25-038619.md) | [(25.9) d](/filings/0001628280-25-050422.md) | [16.2 d](/filings/0001628280-26-013569.md) | [(48.9)](/filings/0001628280-26-031726.md) | [(41.4) d](/filings/0001628280-26-053883.md) | [(35.0) d](/filings/0001628280-25-050422.md) | [(37.3) d](/filings/0001628280-26-013569.md) | [(42.7)](/filings/0001628280-26-031726.md) | [(41.0) d](/filings/0001628280-26-053883.md) |
| Capital expenditure | $m | [2.9 d](/filings/0001628280-24-047130.md) | [1.8 d](/filings/0001628280-25-008884.md) | [2.3](/filings/0001628280-25-023486.md) | [1.9 d](/filings/0001628280-25-038619.md) | [1.3 d](/filings/0001628280-25-050422.md) | [1.8 d](/filings/0001628280-26-013569.md) | [2.4](/filings/0001628280-26-031726.md) | [1.6 d](/filings/0001628280-26-053883.md) | [0.2 d](/filings/0001628280-25-050422.md) | [0.3 d](/filings/0001628280-26-013569.md) | [0.2](/filings/0001628280-26-031726.md) | [0.0 d](/filings/0001628280-26-053883.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [22.2](/filings/0001628280-23-036777.md) | [89.1](/filings/0001628280-24-022473.md) | [90.5](/filings/0001628280-24-035893.md) | [91.8](/filings/0001628280-24-047130.md) | [104](/filings/0001628280-25-023486.md) | [119](/filings/0001628280-25-038619.md) | [120](/filings/0001628280-25-050422.md) | [131](/filings/0001628280-26-031726.md) | [129](/filings/0001628280-26-053883.md) | [161](/filings/0001628280-25-050422.md) | [177](/filings/0001628280-26-031726.md) | [177](/filings/0001628280-26-053883.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 181,376,856 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-053883.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.